Concepedia

Jennifer L. Spratlin

JL

Statistics

Publications

47

Citations

3.6K

H-Index

27

Active since

2004

Affiliations

University of Alberta(Current)

Princess Margaret Cancer Centre

Memorial Sloan Kettering Cancer Center

BC Cancer Agency

University of Calgary

Jennifer L. Spratlin is an author at University of Alberta specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2004–2024

47

Publications

47

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G<sub>1</sub> Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens et al. · Journal of Clinical Oncology · 2010 · 557 citations · Full text

, , +17

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2017 · 508 citations · Full text

, , +17

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

Jennifer L. Spratlin, Randeep Sangha, Darryl Glubrecht et al. · Clinical Cancer Research · 2004 · 425 citations

, , +13

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Asim Amin, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2014 · 231 citations

, , +17

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff et al. · Journal for ImmunoTherapy of Cancer · 2018 · 180 citations · Full text

, , +17

1–5 of 47